ALV003 Named a Top 10 Inflammatory/Autoimmune Project to Watch

AVL003 has shown promise as a drug to help those with celiac disease cope with the serious problems related to autoimmune and inflammatory issues caused by the disease. This press release shows that this research is getting some attention, which is greatly needed in this field.

Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of autoimmune and gastrointestinal diseases, announced today that the company’s lead therapeutic
product candidate for celiac disease, ALV003, has been selected by Windhover and its advisors as one of “The Top 10 Inflammatory/Autoimmune Projects to Watch in 2012.” This is the second year that ALV003 has been named to the Top 10 list.

Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology and medical device industries. Alvine has been invited to present at Windhover’s Therapeutic Area Partnerships Conference on December 1, 2011 in Boston, MA.

“We are pleased that ALV003 has the rare privilege of being included for a second consecutive year on this prestigious list,” said Abhay Joshi, Ph.D., Alvine’s President and Chief Executive Officer. “The selection, along with our recently announced Phase 2a clinical trial results, validates our belief in the potential value of new therapeutics for use in the treatment of celiac disease.”

Projects are selected by committee based on a rigorous review of the most attractive inflammatory/autoimmune opportunities in the drug industry. The selection criteria include: demonstration of high unmet medical need, large market potential, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications and corporate stability.

“In the current competitive drug development environment, very few projects rise to the level of being recognized in the top 10 list more than once,” said David Cassak, VP, Content, Windhover Conferences and Elsevier Business Intelligence. “The selection of Alvine’s ALV003 as one of the Top 10 Projects to Watch for a second consecutive year is a highly unusual and exceptional honor.” Alvine recently reported results of a Phase 2a study of ALV003 in well-controlled celiac disease patients that demonstrated for the first time, in a controlled clinical trial, that a drug has the potential to diminish gluten-induced injury in celiac disease patients.

Details of the study can be found on

As the trials progress, the future of ALV003 looks good and maybe one day we will have medication that can assist the celiac patient.


Leave a Reply

You must be logged in to post a comment.